A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

被引：14
|
作者：
Isakoff, S. J. [1 ]
Overmoyer, B. [1 ]
Tung, N. M. [1 ]
Gelman, R. S. [1 ]
Habin, K. [1 ]
Qian, J. [1 ]
Giranda, V. [1 ]
Shepherd, S. [1 ]
Garber, J. E. [1 ]
Ellisen, L. W. [1 ]
Winer, E. P. [1 ]
Goss, P. E. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-16-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-16-05
引用
收藏
页数：1
相关论文
共 50 条
  • [21] BRCA1/2 germline mutations and response to PARP inhibitor treatment in lung cancer.
    Fang, Wenfeng
    Cai, Xiuyu
    Zhou, Huaqiang
    Wang, Yinguang
    Zhang, Yaxiong
    Hong, Shaodong
    Shao, Yang
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
    Huggins-Puhalla, Shannon Leigh
    Han, Hyo S.
    Dieras, Veronique
    Friedlander, Michael
    Somlo, George
    Arun, Banu
    Wildiers, Hans
    Kaufman, Bella
    Ayoub, Jean-Pierre M.
    Shah, Melissa
    Burmedi, David
    Qin, Qin
    Qian, Jane
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [23] Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
    Puhalla, Shannon
    Han, Hyo S.
    Dieras, Veronique
    Friedlander, Michael
    Somlo, George
    Arun, Banu
    Wildiers, Hans
    Kaufman, Bella
    Ayoub, Jean-Pierre M.
    Shan, Melissa
    Burmedi, David
    Qin, Qin
    Qian, Jane
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Parp inhibitors for brca1/2mutation associated breast cancer
    Tutt, A. N. J.
    CANCER RESEARCH, 2022, 82 (04)
  • [25] Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
    Tan, A. R.
    Toppmeyer, D.
    Stein, M. N.
    Moss, R. A.
    Gounder, M.
    Lindquist, D. C.
    Ji, J. J.
    Chen, A. P.
    Egorin, M. J.
    Kiesel, B.
    Beumer, J. H.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Combination of PARP inhibitor ABT-888 with NO-donor SNAP sensitizes BRCA1 positive cancer cell lines to ionizing radiation
    Wilson, Aaron
    Yakovlev, Vasily A.
    CANCER RESEARCH, 2015, 75
  • [27] Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.
    McAndrew, Nicholas Patrick
    Maxwell, Kara Noelle
    Stopfer, Jill
    Powers, Jacquelyn
    Brandt, Amanda C.
    Long, Jessica M.
    Nathanson, Katherine L.
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
    Rodler, Eve T.
    Kurland, Brenda F.
    Griffin, Melissa
    Gralow, Julie R.
    Porter, Peggy
    Yeh, Rosa F.
    Gadi, Vijayakrishna K.
    Guenthoer, Jamie
    Beumer, Jan H.
    Korde, Larissa
    Strychor, Sandra
    Kiesel, Brian F.
    Linden, Hannah M.
    Thompson, John A.
    Swisher, Elizabeth
    Chai, Xiaoyu
    Shepherd, Stacie
    Giranda, Vincent
    Specht, Jennifer M.
    CLINICAL CANCER RESEARCH, 2016, 22 (12) : 2855 - 2864
  • [29] Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
    Clark, Caroline C.
    Weitzel, Jeffrey N.
    O'Connor, Timothy R.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1948 - 1958
  • [30] Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
    Han, H. S.
    Dieras, V.
    Robson, M. E.
    Palacova, M.
    Marcom, P. K.
    Jager, A.
    Bondarenko, I.
    Citrin, D.
    Campone, M.
    Telli, M. L.
    Domchek, S. M.
    Friedlander, M.
    Man, B. Kauf
    Ratajczak, C.
    Coates, A.
    Bonnet, P.
    Qin, Q.
    Qian, J.
    Giranda, V. L.
    Shepherd, S. P.
    Isakoff, S. J.
    Puhalla, S.
    CANCER RESEARCH, 2017, 77
12345